Fonar sells outpatient operation
Wholly owned Fonar subsidiary Health Management Corporation of America (HMCA) sold its stock April 8 in A&A Services, a physician practice management services organization that manages four primary-care practices in New York City. The sale was made to
Wholly owned Fonar subsidiary Health Management Corporation of America (HMCA) sold its stock April 8 in A&A Services, a physician practice management services organization that manages four primary-care practices in New York City. The sale was made to the former owners for $3 million cash. The buyers also forgave Fonar debts of about $1.1 million. About five years ago HMCA purchased A&A for $10 million payable in a combination of cash, promissory notes, and HMCA stock. Fonar emphasized that no family, business, or other material relationship exists between the buyers and any directors or officers of Fonar, HMCA, or its respective affiliates.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
